Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche presents cancer findings at ESMO

Roche presents cancer findings at ESMO

15th September 2008

Roche is presenting over 100 abstracts on its treatments for lung, gastric and brain cancers at Europe’s biggest congress on the disease in Stockholm, Sweden.

Included in the studies the company will present to the European Society for Medical Oncology (ESMO) are the latest data on drugs such as Avastin (bevacizumab), Herceptin (trastuzumab), Tarceva (erlotinib) and Xeloda (capecitabine).

It will also provide an update on the phase III trials of its new breast cancer treatment, pertuzumab, the company has confirmed.

Specific data will include the final results of Roche’s AVAiL study to confirm the use of Avastin as a primary treatment for non-small cell lung cancer, the most common form of the disease.

It will also provide data on the oral chemotherapy treatment Xeloda, which the company says proved superior to the intravenous 5-FU treatment in helping patients to live longer with an improved quality of life.

William Burns, chief executive officer of Roche’s pharmaceutical division, said: "The results of these studies will be welcome news for patients, their families, and the oncology community who currently have few options for treating debilitating cancers like stomach, lung and brain cancer."

Roche was founded in Basel, Switzerland in 1896.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.